Compare FNRN & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNRN | ADAG |
|---|---|---|
| Founded | 1910 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.4M | 222.2M |
| IPO Year | 2000 | 2020 |
| Metric | FNRN | ADAG |
|---|---|---|
| Price | $17.50 | $1.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.91 |
| AVG Volume (30 Days) | 125.3K | ★ 300.8K |
| Earning Date | 10-29-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.42 | N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $129.59 |
| P/E Ratio | $17.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.72 | $1.27 |
| 52 Week High | $19.25 | $4.85 |
| Indicator | FNRN | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 54.39 | 37.17 |
| Support Level | $16.19 | N/A |
| Resistance Level | $18.49 | $4.16 |
| Average True Range (ATR) | 0.92 | 0.32 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 54.55 | 33.94 |
First Northern Community Bancorp is a bank holding company for a community bank, First Northern Bank of Dixon. It conducts general banking activities, including collecting deposits and originating loans, and serves Solano, Yolo, Sacramento, Placer, El Dorado, and Contra Costa Counties. It offers a broad range of alternative investment products and services, equipment leasing, credit cards, merchant card processing, payroll services, and limited international banking services. The bank generates the majority of its revenue by providing various products and services to small and medium-sized businesses and individuals. including accepting demand, interest bearing transaction, savings, and time deposits, and making commercial, consumer, and real estate-related loans.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.